101-19: New Evidence, New Delivery Methods, New Opportunities for Engaging Clients

4.5 (2 votes)

101-19:  New Evidence, New Delivery Methods,  New Opportunities for Engaging Clients

Consider cutting edge scientific discoveries for treating schizophrenia. Update your background knowledge of the long-range costs, and the treatment options for this mental illness.


Presenter:
  Rebecca S Roma MD, MBA

Disclosures: The speaker has indicated a significant financial interest or other affiliation with Alkermes, Janssen Pharmaceuticals Inc., Neurocrine, Teva, and Otsuka America Pharmaceutical, Inc. Off-label uses will not be discussed during this presentation. The activity planners have no conflicts of interest to disclose.


Session Length:
  1 hour 24 minutes

Target Audience:  RN, APRN


Learning Outcomes:
Upon completion of this presentation, the participant will be able to:

  1. Describe the course, continuity of care, and costs of schizophrenia.
  2. Explore oral medications and LAIs in a new paradigm for treatment of schizophrenia.

Keywords:  Psychopharmacology, Long Acting Injectables, Schizophrenia

Continuing Nursing Education:
1.5 pharmacology contact hours.  * In order to receive contact hours, you must: Listen to presentation, complete an evaluation, and earn a passing score on the post-test before the expiration date. You will have 5 tries to correctly answer the questions on the post-test and a score of 80% is required to pass. Once you have passed and completed an evaluation, the certificate will be generated online, available for you to print immediately. You cannot earn credit unless all steps are completed.

The American Psychiatric Nurses Association is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.


Originally Presented
17th Annual Clinical Psychopharmacology Institute
Louisville, KY
Friday, June 7, 2019
8:00am - 9:30am


The contact hours for this session expire:  June 30, 2021

Components visible upon registration.